Association of apolipoproteins and lipoprotein(a) with metabolic syndrome: a systematic review and meta-analysis.
Apolipoproteins
Lipoprotein(a)
Metabolic syndrome
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
07 Jul 2023
07 Jul 2023
Historique:
received:
30
05
2023
accepted:
26
06
2023
medline:
10
7
2023
pubmed:
8
7
2023
entrez:
7
7
2023
Statut:
epublish
Résumé
Apolipoproteins and lipoprotein(a) are associated with various cardiometabolic diseases, including insulin resistance, diabetes mellitus, hypertension, dyslipidemia, among others. This systematic review and meta-analysis was conducted to evaluate the association of these markers with metabolic syndrome (MetS). We ran a systematic search through PubMed, Scopus, Embase, Ovid/Medline, and Web of Science on March 15, 2023. No language or date restrictions were applied. The only synthesised effect measure reported was the odds ratio (OR) with its corresponding 95% confidence interval (95% CI). We utilised the random-effects model for the quantitative synthesis. We analysed 50 studies (n = 150 519) with different definitions for MetS. Increased ApoB values were associated with MetS (OR = 2.8; 95% CI: 2.44-3.22; p < 0.01, I Increased values of ApoB and ApoB/ApoA1 ratio are associated with MetS, while decreased values of ApoA1 and Lp(a) are associated with MetS. These findings suggest that these lipid markers may serve as potential indicators for identifying subjects at risk of developing MetS. However, further research is required to elucidate the underlying mechanisms of these associations.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Apolipoproteins and lipoprotein(a) are associated with various cardiometabolic diseases, including insulin resistance, diabetes mellitus, hypertension, dyslipidemia, among others. This systematic review and meta-analysis was conducted to evaluate the association of these markers with metabolic syndrome (MetS).
METHODS
METHODS
We ran a systematic search through PubMed, Scopus, Embase, Ovid/Medline, and Web of Science on March 15, 2023. No language or date restrictions were applied. The only synthesised effect measure reported was the odds ratio (OR) with its corresponding 95% confidence interval (95% CI). We utilised the random-effects model for the quantitative synthesis.
RESULTS
RESULTS
We analysed 50 studies (n = 150 519) with different definitions for MetS. Increased ApoB values were associated with MetS (OR = 2.8; 95% CI: 2.44-3.22; p < 0.01, I
CONCLUSIONS
CONCLUSIONS
Increased values of ApoB and ApoB/ApoA1 ratio are associated with MetS, while decreased values of ApoA1 and Lp(a) are associated with MetS. These findings suggest that these lipid markers may serve as potential indicators for identifying subjects at risk of developing MetS. However, further research is required to elucidate the underlying mechanisms of these associations.
Identifiants
pubmed: 37420190
doi: 10.1186/s12944-023-01860-w
pii: 10.1186/s12944-023-01860-w
pmc: PMC10327137
doi:
Substances chimiques
Lipoprotein(a)
0
Apolipoproteins
0
Apolipoproteins B
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
98Informations de copyright
© 2023. The Author(s).
Références
Metab Syndr Relat Disord. 2010 Dec;8(6):515-22
pubmed: 20715933
Arterioscler Thromb Vasc Biol. 2006 Feb;26(2):406-10
pubmed: 16306426
J Clin Epidemiol. 2016 Jul;75:40-6
pubmed: 27005575
Coron Artery Dis. 2008 May;19(3):125-31
pubmed: 18418227
Ann Epidemiol. 2004 Oct;14(9):686-95
pubmed: 15380800
Travel Med Infect Dis. 2021 Nov-Dec;44:102200
pubmed: 34752921
Curr Opin Lipidol. 2007 Dec;18(6):633-7
pubmed: 17993808
Indian J Urol. 2021 Jul-Sep;37(3):217-225
pubmed: 34465950
Arch Gerontol Geriatr. 2006 Jan-Feb;42(1):35-45
pubmed: 16046242
Stat Med. 2000 Nov 30;19(22):3127-31
pubmed: 11113947
Curr Opin Lipidol. 2005 Jun;16(3):287-94
pubmed: 15891389
J Am Coll Cardiol. 2010 May 11;55(19):2160-7
pubmed: 20447543
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Int J Mol Sci. 2022 Jan 12;23(2):
pubmed: 35054972
Atherosclerosis. 2016 Apr;247:58-63
pubmed: 26868509
Stroke. 2004 Oct;35(10):2248-52
pubmed: 15345795
Lipids Health Dis. 2014 May 14;13:81
pubmed: 24886173
J Am Coll Cardiol. 2010 Sep 28;56(14):1113-32
pubmed: 20863953
BMC Geriatr. 2022 Dec 19;22(1):979
pubmed: 36536296
Endocrinol Metab Clin North Am. 2014 Mar;43(1):1-23
pubmed: 24582089
Exp Mol Pathol. 2011 Oct;91(2):622-5
pubmed: 21801720
J Interferon Cytokine Res. 2020 Feb;40(2):71-74
pubmed: 31599692
Diagnostics (Basel). 2020 Jul 23;10(8):
pubmed: 32717783
Int J Cardiol. 2007 Mar 20;116(2):194-200
pubmed: 16828905
Int J Clin Pract. 2022 Aug 10;2022:5450173
pubmed: 36016824
Atherosclerosis. 2005 May;180(1):161-9
pubmed: 15823289
Salud Publica Mex. 2021 Nov 05;63(6, Nov-Dic):713-724
pubmed: 35099910
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
J Appl Lab Med. 2016 Sep 1;1(2):214-229
pubmed: 27840858
Endocrinol Diabetes Nutr (Engl Ed). 2019 Oct;66(8):502-511
pubmed: 31182348
Clin Chim Acta. 2020 Apr;503:128-135
pubmed: 31981585
Int J Cardiol. 2013 Oct 3;168(3):2678-83
pubmed: 23545148
BMC Med Res Methodol. 2005 Apr 20;5:13
pubmed: 15840177
Open Med (Wars). 2022 Dec 06;17(1):1915-1926
pubmed: 36561845
Eur J Prev Cardiol. 2020 Aug;27(12):1255-1268
pubmed: 31475865
Angiology. 2008 Jun-Jul;59(3):335-41
pubmed: 18388068
Biol Pharm Bull. 2016;39(1):1-24
pubmed: 26725424
Eur Heart J. 2007 Nov;28(21):2637-43
pubmed: 17766927
Front Mol Biosci. 2022 Jun 08;9:854624
pubmed: 35755826
Nutr Metab Cardiovasc Dis. 2013 Dec;23(12):1239-46
pubmed: 23786824
Ann Clin Biochem. 2011 Nov;48(Pt 6):498-515
pubmed: 22028427
Endocrine. 2015 Jun;49(2):404-14
pubmed: 25306891
Diabetes Metab Res Rev. 2019 Sep;35(6):e3158
pubmed: 30908791
Int J Obes (Lond). 2007 Jul;31(7):1119-25
pubmed: 17299378
Atherosclerosis. 2013 Feb;226(2):496-501
pubmed: 23273962
PLoS One. 2014 Aug 12;9(8):e104833
pubmed: 25118169
Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1861-6
pubmed: 20539018
Physiol Res. 2017 Apr 5;66(Suppl 1):S113-S120
pubmed: 28379036
BMJ Open. 2018 Dec 4;8(12):e021580
pubmed: 30518581
Saudi Med J. 2007 Mar;28(3):339-46
pubmed: 17334456
Gerontology. 2008;54(6):361-4
pubmed: 18622136
Atherosclerosis. 2008 Mar;197(1):333-8
pubmed: 17628565
Biomed Environ Sci. 2019 Jul;32(7):477-485
pubmed: 31331432
Diabetologia. 2006 Jul;49(7):1637-46
pubmed: 16752182
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Heart Vessels. 2005 Nov;20(6):290-5
pubmed: 16314912
Clin Chim Acta. 2009 Aug;406(1-2):129-33
pubmed: 19539616
Diabet Med. 1998 Jul;15(7):539-53
pubmed: 9686693
Int J Obes Relat Metab Disord. 2003 Oct;27(10):1283-9
pubmed: 14513078
J Clin Endocrinol Metab. 2005 Apr;90(4):2264-9
pubmed: 15687341
Dtsch Arztebl Int. 2022 Apr 15;119(15):270-276
pubmed: 35331368
Endocrinol Metab (Seoul). 2015 Jun;30(2):208-15
pubmed: 26194080
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
Diabetes Metab J. 2012 Feb;36(1):56-63
pubmed: 22363922
Front Endocrinol (Lausanne). 2022 Jul 14;13:935776
pubmed: 35909551
Diabetes Metab Syndr. 2017 Jul - Sep;11(3):179-182
pubmed: 27600468
Atherosclerosis. 2008 Mar;197(1):84-94
pubmed: 17868679
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765
Am Heart J. 2004 Jan;147(1):106-12
pubmed: 14691427
Int J Clin Pract. 2021 Nov;75(11):e14578
pubmed: 34181800
Am J Cardiol. 2006 Nov 15;98(10):1369-73
pubmed: 17134631
Heliyon. 2019 Jul 03;5(7):e02033
pubmed: 31317083
Clin Endocrinol (Oxf). 2012 Nov;77(5):699-706
pubmed: 22211563
J Diabetes. 2019 Sep;11(9):752-760
pubmed: 30652427
Biomark Med. 2016;10(4):397-402
pubmed: 26999640
PLoS One. 2017 Aug 2;12(8):e0182217
pubmed: 28767713
Arch Cardiol Mex. 2020 Dec 01;91(3):307-314
pubmed: 33268905
Chronic Dis Can. 2010 Dec;31(1):33-8
pubmed: 21213617
Metabolism. 2010 May;59(5):677-82
pubmed: 19914667
Front Endocrinol (Lausanne). 2022 Jan 05;12:773781
pubmed: 35069437